Is Blincyto a type of immunotherapy?
Blincyto is a type of immunotherapy called a bispecific monoclonal antibody. This means that it binds to two different molecules at the same time – a protein called CD19 which exists on the surface of B-cell leukemia or lymphoma cells and a protein called CD3 which is expressed on T cells (a specific type of immune system cell). Blincyto may also be called a targeted treatment.
References
- Blincyto Package Insert. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf
Related medical questions
- What are monoclonal antibodies?
- How much does Blincyto (blinatumomab) cost?
- Is Blincyto (blinatumomab) chemotherapy?
- How is Blincyto taken / administered?
Drug information
- Blincyto Information for Consumers
- Blincyto prescribing info & package insert (for Health Professionals)
- Side Effects of Blincyto (detailed)
Related support groups
- Blincyto (5 questions, 4 members)
